January 13, 2016
The U.S. Department of Health and Human Services, Centers for Medicare & Medicaid Services (CMS) awarded IMPAQ International a new contract, Part D Enhanced Medication Therapy Management Technical Implementation Support, to provide technical implementation support services to CMS prior to and during the five-year Part D Enhanced Medication Therapy Management (MTM) Model test. The support services include data collection, analysis, and performance monitoring of model participants.
MTM programs were included as a quality-improvement requirement under the Medicare Modernization Act of 2003 to improve medication use, outcomes, and to reduce the risk of adverse events. However, the current MTM model does not offer Part D sponsors financial incentives to provide a comprehensive MTM program or to drive beneficiaries’ participation in MTM service offerings. Under this new contract, IMPAQ will assist CMS in implementing a new performance-based payment model.
“We are excited to continue to work with CMS on enhancing healthcare in the United States,” Vice President of IMPAQ’s Health Division Paul Gorrell, PhD, said. “The implementation of the Enhanced MTM Model is a critical step toward achieving CMS’s Quality Strategy goals.”
IMPAQ’s team includes experts in CMS program implementation, MTM, quality measurement, and Medicare data analysis within CMS data systems. IMPAQ serves as the prime contractor and is responsible for project management, quality assurance, and documentation across all tasks. Econometrica, Inc. and the University of Maryland School of Pharmacy’s Center for Innovative Pharmacy Solutions (UMCIPS) are subcontractors on this award.
Ilene Harris, PharmD, PhD, a health services researcher and expert on drug use in older adults, leads the project team. “The Enhanced MTM Model is an opportunity for prescription drug plan sponsors to identify and implement innovative strategies to optimize Medicare beneficiaries’ medication use and outcomes,” Dr. Harris noted.
This contract, which was awarded under CMS’s Research, Measurement, Assessment, Design and Analysis (RMADA) procurement program, builds upon IMPAQ’s ongoing work in monitoring and evaluating the Medicare Part D prescription drug program. IMPAQ serves as the prime contractor for Evaluation and Performance of Medicare Part D Organizations: Business Rule Logic for Performance Metrics and Composite Scoring for Plan Ratings and for Development of Medicare Advantage, Prescription Drug Plan, & Financial Alignment Demonstrations Monitoring Methods for Medication Therapy Management & Outbound Call Verification. Through each of these projects, IMPAQ and CMS are focusing on improving medication management among Medicare beneficiaries.
About IMPAQ International
IMPAQ evaluates and enhances the policies, programs, and products of public and private sector organizations. We drive value with innovative thinking and rigorous approaches that deliver meaningful insight and real world impact. Learn more at www.impaqint.com.